Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Malaria is a critical public health problem resulting in substantial morbidity and mortality, particularly in developing countries. Owing to the development of resistance toward current therapies, novel approaches to accelerate the development efforts of new malaria therapeutics are urgently needed. There have been significant advancements in the development of in vitro and in vivo experiments that generate data used to inform decisions about the potential merit of new compounds. A comprehensive disease-drug model capable of integrating discrete data from different preclinical and clinical components would be a valuable tool across all stages of drug development. This could have an enormous impact on the otherwise slow and resource-intensive process of traditional clinical drug development.

Original publication

DOI

10.1146/annurev-pharmtox-010715-103429

Type

Journal article

Journal

Annu Rev Pharmacol Toxicol

Publication Date

06/01/2018

Volume

58

Pages

567 - 582

Keywords

controlled human malaria infection, disease-drug model, malaria, model-informed drug development, pharmacodynamics, pharmacokinetics